Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CSBRNASDAQ:GMDANASDAQ:NTGNNASDAQ:OTLK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSBRChampions Oncology$4.90-0.8%$10.15$7.19▼$14.68$67.15M0.45,655 shs3,382 shsGMDAGamida Cell$0.04-39.0%$0.35$0.03▼$2.51$3.81M1.038.13 million shs89.18 million shsNTGNNeon Therapeutics$3.07$3.03$0.88▼$6.25$88.93M-0.81516,108 shsN/AOTLKOutlook Therapeutics$11.94+27.4%$8.21$4.00▼$40.60$155.34MN/A1.43 million shs1.55 million shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSBRChampions Oncology-2.58%-7.89%-12.03%-9.43%+17.22%GMDAGamida Cell-39.02%-91.04%-90.55%-91.25%-95.31%NTGNNeon Therapeutics0.00%0.00%0.00%0.00%0.00%OTLKOutlook Therapeutics+27.43%+69.60%+34.79%+51.52%-43.14%Did You Get Your Free Bitcoin Yet? (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCSBRChampions Oncology4.0363 of 5 stars3.33.00.04.50.64.20.0GMDAGamida Cell1.4842 of 5 stars3.42.00.00.02.20.80.6NTGNNeon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOTLKOutlook Therapeutics3.528 of 5 stars4.44.00.00.03.80.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSBRChampions Oncology2.50Moderate Buy$7.5053.06% UpsideGMDAGamida Cell2.75Moderate Buy$4.7513,057.89% UpsideNTGNNeon TherapeuticsN/AN/AN/AN/AOTLKOutlook Therapeutics2.88Moderate Buy$46.43288.82% UpsideCurrent Analyst RatingsLatest CSBR, OTLK, GMDA, and NTGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024OTLKOutlook TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.003/25/2024OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.003/13/2024CSBRChampions OncologyCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold2/16/2024OTLKOutlook TherapeuticsCapital One FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight2/15/2024OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$60.001/29/2024GMDAGamida CellJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform1/25/2024OTLKOutlook TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$31.401/25/2024OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$40.0012/29/2023OTLKOutlook TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $40.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSBRChampions Oncology$53.87M1.24N/AN/A($0.15) per share-32.67GMDAGamida Cell$1.78M2.14N/AN/A($0.11) per share-0.33NTGNNeon TherapeuticsN/AN/AN/AN/A$0.50 per shareN/AOTLKOutlook TherapeuticsN/AN/AN/AN/A($1.11) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSBRChampions Oncology-$5.34M-$0.72N/A∞N/A-19.76%-850.72%-32.62%7/22/2024 (Estimated)GMDAGamida Cell-$79.38M-$0.63N/A0.09N/AN/AN/A-56.35%5/20/2024 (Estimated)NTGNNeon Therapeutics-$79.78M-$2.86N/AN/AN/AN/A-199.09%-137.14%N/AOTLKOutlook Therapeutics-$58.98M-$4.00N/AN/AN/AN/A-3,741.39%-132.37%5/20/2024 (Estimated)Latest CSBR, OTLK, GMDA, and NTGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/14/2024Q1 2024OTLKOutlook Therapeutics-$1.00-$0.80+$0.20-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCSBRChampions OncologyN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/ANTGNNeon TherapeuticsN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSBRChampions OncologyN/A0.600.60GMDAGamida Cell213.143.323.20NTGNNeon Therapeutics0.431.583.00OTLKOutlook TherapeuticsN/A0.440.44OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSBRChampions Oncology41.30%GMDAGamida Cell50.34%NTGNNeon Therapeutics54.71%OTLKOutlook Therapeutics11.20%Insider OwnershipCompanyInsider OwnershipCSBRChampions Oncology45.69%GMDAGamida Cell3.40%NTGNNeon Therapeutics38.93%OTLKOutlook Therapeutics5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCSBRChampions Oncology14313.59 million7.38 millionOptionableGMDAGamida Cell143105.59 million102.00 millionOptionableNTGNNeon Therapeutics10228.97 millionN/ANot OptionableOTLKOutlook Therapeutics2413.01 million12.32 millionNot OptionableCSBR, OTLK, GMDA, and NTGN HeadlinesSourceHeadlineHow to fight the new Windows Outlook app and keep Mail…for nowpcworld.com - March 28 at 2:25 PMOutlook Therapeutics (NASDAQ:OTLK) Upgraded by BTIG Research to "Buy"americanbankingnews.com - March 28 at 4:20 AMOutlook Therapeutics, Inc. (NASDAQ:OTLK) Short Interest Down 93.3% in Marchmarketbeat.com - March 27 at 10:15 PMBuy Rating for Outlook Therapeutics: Promising FDA Developments and Strong Financial Position Support $50 Price Targetmarkets.businessinsider.com - March 27 at 3:13 PMOutlook Therapeutics shares rise after 'buy' rating from BTIGmsn.com - March 27 at 3:13 PMOutlook Therapeutics (NASDAQ:OTLK) Upgraded by BTIG Research to Buymarketbeat.com - March 27 at 8:30 AMQ2 2024 Earnings Estimate for Outlook Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:OTLK)americanbankingnews.com - March 27 at 6:02 AMOutlook Therapeutics (NASDAQ:OTLK) Given New $30.00 Price Target at HC Wainwrightamericanbankingnews.com - March 26 at 3:56 AMOutlook Therapeutics: Buy Rating Affirmed Amid Positive European Developments and Anticipated U.S. Market Successmarkets.businessinsider.com - March 25 at 7:36 PMHC Wainwright Raises Outlook Therapeutics (NASDAQ:OTLK) Price Target to $30.00marketbeat.com - March 25 at 8:48 AMBuy Rating Affirmed for Outlook Therapeutics: European Endorsement and Pivotal US Study Progress Signal Strong Market Potentialmarkets.businessinsider.com - March 25 at 5:33 AMOutlook Therapeutics Surges On Positive CHMP Opinion For ONS-5010nasdaq.com - March 24 at 7:33 PMWhy Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?msn.com - March 22 at 3:36 PMOutlook Therapeutics Shares Rise Premarket on CHMP Backing of Wet AMD Drugmarketwatch.com - March 22 at 10:35 AMCanopy Growth, Capricor Therapeutics, GT Biopharma among healthcare moversmsn.com - March 22 at 10:35 AMOutlook Therapeutics Receives Positive CHMP Opinion For ONS-5010 To Treat Wet AMDmarkets.businessinsider.com - March 22 at 10:35 AMOutlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDglobenewswire.com - March 22 at 7:35 AMQ2 2024 EPS Estimates for Outlook Therapeutics, Inc. (NASDAQ:OTLK) Raised by Analystamericanbankingnews.com - March 22 at 2:18 AMAll You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buyzacks.com - March 21 at 1:01 PMResearch Analysts Issue Forecasts for Outlook Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:OTLK)marketbeat.com - March 21 at 8:04 AMBuy Rating Affirmed for Outlook Therapeutics Amidst Strong Financial Positioning and Advancing Clinical Trialsmarkets.businessinsider.com - March 19 at 5:22 AMOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from Brokeragesamericanbankingnews.com - March 19 at 4:34 AMOutlook Therapeutics® Announces Closing of Private Placement of up to $159 Millionglobenewswire.com - March 18 at 5:10 PMGlobal Sustainable Packaging Market Outlook & Forecast 2024-2029: Biodegradable Innovations and E-Commerce Driving Growthfinance.yahoo.com - March 18 at 9:20 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsChampions OncologyNASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Gamida CellNASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.Neon TherapeuticsNASDAQ:NTGNNeon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Outlook TherapeuticsNASDAQ:OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.